Multiple Choice
Recombinant DNA-based products are slow to reach the marketplace because of
A) the adverse effects of gene cloning.
B) the lack of technological advances in gene cloning.
C) the lack of safety involved in such methods.
D) the cost and duration of research.
Correct Answer:
Verified
Correct Answer:
Verified
Q26: Transgenic organisms carry the transgene in<br>A)every cell.<br>B)gametes
Q27: A drug produced using recombinant DNA technology
Q28: In 2010,a federal judge in the U.S.ruled
Q29: Courts allow patenting complementary DNA (cDNA)because<br>A)its exact
Q30: One of the earliest uses of biotechnology
Q32: The first patent on a living organism
Q33: A gene expression microarray has<br>A)an entire genome
Q34: Most of the effort involved in recombinant
Q35: Restriction enzymes are useful in creating recombinant
Q36: Patent law as it pertains to biotechnology